unyango lwe-renal cell carcinoma

Unyango lwe-renal cell carcinoma (RCC) ibandakanya iindlela ezahlukeneyo, kubandakanywa utyando, unyango olujoliswe kuyo, i-immunotherapy, kunye nonyango lwe-radiation. Ukhetho lwe unyango kuxhomekeke kwizinto ezifana nenqanaba lomhlaza, impilo yesigulana ngokubanzi, kunye nokukhethwa komntu ngamnye. Ukufunyaniswa kwangethuba kunye nokungenelela ngexesha kubalulekile ekuphuculeni iziphumo.Ukuqonda iRenal Cell CarcinomaI-Renal cell carcinoma (RCC) lolona hlobo luqhelekileyo lomhlaza wezintso kubantu abadala. Isuka kwilayini yeproximal convoluted tubule, inxalenye yezintso ehluza igazi kwaye isuse inkunkuma. Ngelixa oyena nobangela we-RCC ungasoloko ucacile, izinto ezithile zomngcipheko zinxulunyaniswa nokwanda kwamathuba okuba sisifo. Le mingcipheko ibandakanya ukutshaya, ukutyeba, uxinzelelo lwegazi oluphezulu, kunye neemeko zofuzo ezifana nesifo se-von Hippel-Lindau (VHL). Nge IZiko loPhando ngoMhlaza laseShandong Baofa, sizimisele ukubonelela ngolwazi olubanzi kunye nokuqhubela phambili unyango iinketho kwizigulane ze-RCC.Iintlobo zeRenal Cell CarcinomaKukho iindidi ezininzi ze-RCC, nganye ineempawu ezahlukileyo kunye neempendulo ezinokuba nezahlukeneyo unyango. Ii-subtypes eziqhelekileyo ziquka: Cima iseli RCC: Olu lolona hlobo luxhaphakileyo, lubalelwa malunga ne-70-80% yamatyala. I-Papillary RCC: Uhlobo lwesibini oluqhelekileyo, olumele malunga ne-10-15% yamatyala. I-Chromophobe RCC: Uhlobo oluncinci, olwenza malunga ne-5% yamatyala. Ukuqokelela umbhobho we-RCC: Uhlobo olunqabileyo nolundlongondlongo lwe-RCC.UKhetho loNyango lweRenal Cell Carcinoma unyango indlela ye-RCC ixhomekeke kwizinto ezininzi, kubandakanywa inqanaba lomhlaza, impilo yesigulana iyonke, kunye nohlobo oluthile lwe-RCC. Eqhelekileyo unyango iindlela ziquka utyando, unyango ekujoliswe, immunotherapy, kunye nonyango ngemitha. unyango lwe-renal cell carcinoma, ngakumbi xa umhlaza ubekwe kwindawo kwizintso. Ukhetho lotyando lubandakanya: I-nephrectomy enkulu: Oku kubandakanya ukususwa ngokupheleleyo kwezintso ezichaphazelekayo, kunye nezicubu ezijikelezileyo ezifana ne-adrenal gland kunye ne-lymph nodes. I-nephrectomy engaphelelanga: Oku kubandakanya ukususa kuphela ithumba kunye nomda omncinci wezicubu eziphilileyo, ukugcinwa kwezintso ezininzi kangangoko kunokwenzeka. Le ndlela ikhethwa ngokuqhelekileyo kumathumba amancinci okanye xa isigulane sinezintso enye kuphela.Unyango olujoliswe kuyo ngamachiza ajolise ngokukodwa kwiimolekyuli ezibandakanyekayo ekukhuleni kweeseli zomhlaza kunye nokuphila. Olu nyango lunokusebenza ngokukodwa kwi-RCC ephezulu. Iindlela zonyango ekujoliswe kuzo zibandakanya: I-VEGF inhibitors: La machiza avimba i-vascular endothelial growth factor (VEGF) indlela, eyimfuneko ekubunjweni kwemithambo yegazi emitsha enikezela ngamathumba. Imizekelo iquka i-sunitinib (Sutent), i-sorafenib (Nexavar), pazopanib (Votrient), i-axitinib (Inlyta), kunye ne-cabozantinib (Cabometyx). i-mTOR inhibitors: La machiza avimba i-mammalian target of rapamycin (mTOR) indlela, elawula ukukhula kweeseli kunye nemetabolism. Imizekelo ibandakanya i-temsirolimus (Torisel) kunye ne-everolimus (Afinitor).I-ImmunotherapyImmunotherapy ibopha amandla amajoni omzimba okulwa nomhlaza. Amachiza e-Immunotherapy e-RCC aquka: Izithinteli zokuthintela amajoni omzimba: La machiza avala iiproteni ezithintela amajoni omzimba ekuhlaseleni iiseli zomhlaza. Imizekelo ibandakanya nivolumab (Opdivo), pembrolizumab (Keytruda), ipilimumab (Yervoy), kunye atezolizumab (Tecentriq). I-Nivolumab ihlala idityaniswa kunye ne-ipilimumab yesifo esiphambili. IiCytokines: I-high-dose interleukin-2 (IL-2) kunye ne-interferon-alpha (IFN-α) yi-cytokines enokuvuselela amajoni omzimba. Nangona kunjalo, la machiza anokuba nemiphumo ebalulekileyo kwaye aqhelekanga ukusetyenziswa ngoku ngenxa yokufumaneka kwe-immunotherapies entsha.Unyango lweRadiation TherapyRadiation therapy isebenzisa imitha ephezulu yamandla ukubulala iiseli zomhlaza. Ngokuqhelekileyo ayisiyiyo ephambili unyango lwe-renal cell carcinoma, kodwa inokusetyenziselwa ukulawula iintlungu okanye ezinye iimpawu ezibangelwa ngumhlaza ophezulu oye wasasazeka kwamanye amalungu omzimba. Ngamanye amaxesha isetyenziswa emva kotyando ukuba kukho umngcipheko wokuba umhlaza uza kubuya okanye ukuba elinye ithumba alikwazanga kususwa. I-Stereotactic body radiation therapy (SBRT) inikezela ngeedosi eziphezulu zokusasazeka kwemitha kwindawo ekujoliswe kuyo ngokuchanekileyo kwaye ngamanye amaxesha isetyenziselwa amathumba ezintso.Amanqanaba eRenal Cell Carcinoma kunye noNyangoInqanaba le-RCC ngumba ophambili ekumiseleni okufanelekileyo. unyango ukusondela. Inqanaba lisekelwe kubukhulu kunye nendawo ye-tumor, ingaba isasazeke kwii-lymph nodes ezikufutshane, kwaye ingaba i-metastasized kwizitho ezikude.Inqanaba I-Renal Cell CarcinomaIthumba livalelwe kwizintso kwaye li-7 cm okanye ngaphantsi ububanzi. Unyango ngokuqhelekileyo ibandakanya ukususwa ngotyando kwethumba, mhlawumbi nge-nephrectomy engaphelelanga okanye enzulu.Inqanaba II Renal Cell CarcinomaIthumba likhulu kune-7 cm kodwa lisavalelwe kwizintso. Unyango idla ngokubandakanya i-radical nephrectomy.Inqanaba lesithathu leRenal Cell CarcinomaIthumba liye lanwenwa kwii-lymph nodes ezikufutshane okanye likhule laba yimithambo emikhulu okanye izicubu ezikufutshane. Unyango inokubandakanya i-radical nephrectomy, i-lymph node dissection, kwaye mhlawumbi unyango lwe-adjuvant (umzekelo, unyango olujoliswe kuyo okanye i-immunotherapy) .Inqanaba le-IV Renal Cell CarcinomaUmhlaza uye we-metastasized kwizitho ezikude, njengemiphunga, amathambo, okanye ingqondo. Unyango okukhethwa kukho kunokubandakanya utyando lokususa ithumba eliphambili (i-cytoreductive nephrectomy), unyango olujoliswe kuyo, i-immunotherapy, unyango lwe-radiation, okanye indibaniselwano yezi ndlela. Ulingo lwezonyango lusenokuba lukhetho.Ukuphila neRenal Cell CarcinomaUkuphila ne-RCC kunokuzisa imingeni eyahlukahlukeneyo, ngokomzimba nangokweemvakalelo. Kubalulekile ukuba nenkqubo yenkxaso eyomeleleyo kunye nokufikelela kukhathalelo olubanzi lwezonyango. Izigulane zinokufumana iziphumo ebezingalindelekanga ukusuka unyango, njengokudinwa, isicaphucaphu, urhudo, namaqhakuva esikhumba. Ukulawula ezi ziphumo ebezingalindelekanga yinxalenye ebalulekileyo yokhathalelo lomhlaza. Ukongezelela, ukugcina indlela yokuphila enempilo, kuquka ukutya okunokulinganisela kunye nokuzivocavoca rhoqo, kunokunceda ukuphucula impilo yonke. KwiZiko loPhando ngoMhlaza laseShandong Baofa, iqela lethu elizinikeleyo libonelela ngokhathalelo lovelwano kunye nolomntu ngamnye unyango izicwangciso zokunceda izigulane zilawule i-RCC yazo kunye nokuphucula umgangatho wobomi bazo. Sibekwe kwindawo ye-Jinan Innovation Zone, kwaye uthumo lwethu luhambelana neqhinga elithi 'Yenziwe eChina 2025'. Inkqubela phambili yakutsha nje kwiRenal Cell Carcinoma TreatmentThe field of RCC unyango isoloko ivela, kunye nonyango olutsha kunye neendlela eziphuhliswayo. Inkqubela phambili yamva nje ibandakanya: I-Immunotherapy edibeneyo: Ukudibanisa iziyobisi ezahlukeneyo ze-immunotherapy, ezifana ne-nivolumab kunye ne-ipilimumab, zibonise iziphumo eziphuculweyo kwezinye izigulane ezine-RCC eziphambili. UNyango oluPhuculweyo ekuJoliswe kulo: Izizukulwana ezitsha zonyango ezijoliswe kuzo ziphuhliswa ngokusebenza okuphuculweyo kunye nemiphumo emibi embalwa. Iyeza elenzelwe wena: Abaphandi basebenzela ukuchonga ii-biomarkers ezinokunceda ukuqikelela ukuba zeziphi izigulana ezinokuthi ziphendule ngokuthe ngqo unyangoI-prognosis yeRenal Cell CarcinomaUkuxilongwa kwe-RCC kuyahluka ngokuxhomekeke kwinqanaba lomhlaza, impilo yesigulana ngokubanzi, kunye nempendulo unyango. Ukufunyaniswa kwangethuba kunye nokungenelela kwangethuba kubalulekile ekuphuculeni iziphumo. Izigulane ezine-RCC zasekuhlaleni ezityandwayo zinethuba eliphezulu lokuphiliswa. Nangona kunjalo, i-prognosis ayithandeki kangako kwizigulana ezine-RCC ephezulu. Uphando oluqhubekayo lujolise ekuphuhliseni olutsha kunye nokusebenza kakuhle unyangos ukuphucula i-prognosis kuzo zonke izigulane ezine-RCC. Iimvavanyo zeClinical Ulingo lwezonyango luphononongo lophando oluvavanya amatsha unyangos okanye iindlela ze-RCC. Ukuthatha inxaxheba kulingo lwezonyango kunokubonelela ngofikelelo kunyango lwe-cutting-edge olungekafumaneki ngokubanzi. Izigulane ezinomdla wokufunda ngakumbi malunga nezilingo zeklinikhi kufuneka zithethe nogqirha wabo.Umzekelo weDatha: Amazinga okusinda ngeSiteji seNqanaba le-5-Year Survival Rate Stage I-81-93% Stage II 74-91% Stage III 53-83% Stage IV 8-20% Umthombo: American Cancer Society (www.cancer.org)